body composition comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Common matrix | Plasma or serum | Collected under controlled conditions |
| Primary method | Liquid chromatography–tandem mass spectrometry | Structural specificity |
| Alternative method | Immunoassay | Lower specificity, higher throughput |
| Reporting unit | ng/mL | Concentration in matrix |
| Key validation item | Selectivity | Interference from related peptides |
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
18 January The ONS reports that inflation dropped for the second month running, to 10.5% in December, from 10.7% the previous month. At the two extremes of the ONS's list of "notable movements" that contribute to the overall figure, 'clothing and footwear' price inflation dropped from 7.5% to 6.4%, 'furniture and household goods' dropped from 10.8% to 9.8%, 'food and non-alcoholic beverages' rose from 16.5% to 16.9%, and 'restaurants and hotels' rose from 10.2% to 11.4%. BBC News reports that Church of England bishops will not give their backing to a change in teaching that would allow them to marry same-sex couples, but the Church will offer "prayers of dedication, thanksgiving or God's blessing" to gay couples. 19 January – Prime Minister Rishi Sunak apologises for taking his seat belt off in a moving car to film a social media clip. Lancashire Police later say they are "looking into" the incident. He is issued with a fixed-penalty notice the following day. 20 January The Church of England issues an apology for the "shameful" times it has "rejected or excluded" LGBTQ+ people, while Archbishop of Canterbury Justin Welby says he supports the changes that allow blessings to be offered to gay couples, but says he will not personally use them because he has a "responsibility to the whole communion". The High Court awards £39m in damages against Frimley Health NHS Foundation Trust in Surrey to a girl whose limbs were amputated after she was wrongly diagnosed.
Enantiomers of propranolol, metoprolol, chlorpheniramine, verapamil, hexobarbitaI, methadone and much more drugs have been separated using immobilized β-cyclodextrin. Initially natural CDs have been used as the chiral selector. Later, modified cyclodextrin structures have been prepared by derivatizing the secondary hydroxyl groups present on the CD molecule. Incorporation of these additional functional groups may improve the chiral recognition capability by possibly modifying the chiral pocket and creating extra auxiliary interaction site. This approach enabled to expand the range of target chiral analytes that could be separated. A number of chiral pharmaceuticals has been resolved using derivatized CDs including ibuprofen, suprofen, flurbiprofen from NSAID category and b-blockers like metoprolol and atenolol. A brief list of cyclodextrin-based chiral stationary stationary phases available in the market is furnished in the table below.
== G == G3P – gall – gall-inducing insect – gamete – gametophyte – gastrula – gel electrophoresis – gene – genetic drift – gene duplication – gene pool – genetic code – genetic equilibrium – genetic fingerprint – genetic recombination – genetics – gene regulatory network – genetic carrier – gene therapy – genome – genome project – genomics – genotype – geologic time – George W. Beadle – glucose – glycolipid – glycolysis – glycome – glycomics – glycoprotein – glycoprotein – Gobind Khorana – Golgi apparatus – Gondwana – gradient – gravitational biology – gravitropism – Gregor Mendel – ground tissue – growth curve – Guthrie test
Sources: en.wikipedia.org
==== Pregnancy and breastfeeding ==== During pregnancy and breastfeeding, women must ingest enough nutrients for themselves and their child, so they need significantly more protein and calories during these periods, as well as more vitamins and minerals (especially iron, iodine, calcium, folic acid, and vitamins A, C, and K). In 2001 the FAO of the UN reported that iron deficiency affected 43 percent of women in developing countries and increased the risk of death during childbirth. A 2008 review of interventions estimated that universal supplementation with calcium, iron, and folic acid during pregnancy could prevent 105,000 maternal deaths (23.6 percent of all maternal deaths). Malnutrition has been found to affect three-quarters of UK women aged 16–49 indicated by them having less folic acid than the WHO recommended levels. Frequent pregnancies with short intervals between them and long periods of breastfeeding add an additional nutritional burden.
The two substrates of this enzyme are D-mannitol and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are D-mannose, reduced NADH and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is mannitol:NAD+ 1-oxidoreductase. Other names in common use include MTD, and NAD+-dependent mannitol dehydrogenase.
== Epidemiology == Hypermobility occurs in about 10 to 25% of the population. It is reported more often in females than males. Hypermobile joints are also relatively common among children, though this is often benign.
The study of action potentials has required the development of new experimental methods. The initial work, prior to 1955, was carried out primarily by Alan Lloyd Hodgkin and Andrew Fielding Huxley, who were, along John Carew Eccles, awarded the 1963 Nobel Prize in Physiology or Medicine for their contribution to the description of the ionic basis of nerve conduction. It focused on three goals: isolating signals from single neurons or axons, developing fast, sensitive electronics, and shrinking electrodes enough that the voltage inside a single cell could be recorded. The first problem was solved by studying the giant axons found in the neurons of the squid (Loligo forbesii and Doryteuthis pealeii, at the time classified as Loligo pealeii). These axons are so large in diameter (roughly 1 mm, or 100-fold larger than a typical neuron) that they can be seen with the naked eye, making them easy to extract and manipulate. However, they are not representative of all excitable cells, and numerous other systems with action potentials have been studied. The second problem was addressed with the crucial development of the voltage clamp, which permitted experimenters to study the ionic currents underlying an action potential in isolation, and eliminated a key source of electronic noise, the current IC associated with the capacitance C of the membrane. Since the current equals C times the rate of change of the transmembrane voltage Vm, the solution was to design a circuit that kept Vm fixed (zero rate of change) regardless of the currents flowing across the membrane.
Sources: en.wikipedia.org
=== Endoplasmic reticulum === The discovery of an animal cell AMPylase, followed by the discovery of its ER localisation and that BiP is a prominent substrate for its activity were important breakthroughs. BiP (also known as Grp78) had long been known to undergo an inactivating post-translational modification, but its nature remained elusive. Widely assumed to be ADP-ribosylation, it turns out to be FICD-mediated AMPylation, as inactivating the FICD gene in cells abolished all measurable post-translational modification of BiP. BiP is an ER-localised protein chaperone whose activity is tightly regulated at the transcriptional level via a gene-expression program known as the Unfolded Protein Response (UPR). The UPR is a homeostatic process that couples the transcription rate of BiP (and many other proteins) to the burden of unfolded proteins in the ER (so-called ER stress) to help maintain ER proteostasis. AMPylation adds another rapid post-translational layer of control of BiP's activity, as modification of Thr518 of BiP's substrate-binding domain with an AMP locks the chaperone into an inactive conformation. This modification is selectively deployed as ER stress wanes, to inactivate surplus BiP. However, as ER stress rises again, the same enzyme, FICD, catalyses the opposite reaction, BiP de-AMPylation. An understanding of the structural basis of BiP AMPylation and de-AMPylation is gradually emerging, as are clues to the allostery that might regulate the switch in FICD's activity but important details of this process as it occurs in cells remain to be discovered.
Cefuroxime axetil, sold under the brand name Ceftin among others, is a second generation oral cephalosporin antibiotic. It is an acetoxyethyl ester prodrug of cefuroxime which is effective orally. The activity depends on in vivo hydrolysis and release of cefuroxime tablets. It was patented in 1976 and approved for medical use in 1987.
A conductance deduced from the resulting current between the electrodes and the voltages is reported as ESC, measured in microsiemens (μS), and is proportional to the Cl− flow to the skin surface, that is to say the ability to secrete Cl− ions by eccrine glands, thus providing a quantitative measurement of sudomotor function. The measurement requires no specific patient preparation or medical personnel training. The test lasts less than 3 minutes, and is innocuous and non-invasive. In general, decreased ESC values indicate a higher risk of sudomotor dysfunction, and thus a greater likelihood of small fiber neuropathy. Sudoscan has been shown to be useful in the detection of small fiber neuropathy in patients with and without type 2 diabetes mellitus (T2DM) with a sensitivity of 77 to 87% and a specificity of 67 to 92%, as well as in the screening of diabetic nephropathy. Sudoscan has been compared with other reference tests including Heart Rate Variability (HRV) indices, intraepidermal nerve fiber density, sweat gland nerve fiber density and quantitative sudomotor axon reflex testing (QSART). In addition to diabetes, low ESC values have been reported in association with increased severity of diabetic kidney disease and metabolic syndrome. It has also been shown to be sensitive to change after different interventions in subjects with T2DM. ESC measurements are highly reproducible. Studies have shown ESC values to be dependent on ethnicity. For that purpose, normative reference values have been established on a total of 1,350 healthy participants.
Sources: en.wikipedia.org
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.
Mass spectrometry identifies molecules by mass-to-charge transitions, which reduces interference from related peptides. Immunoassays run faster but can cross-react. Structural confirmation usually requires the mass spectrometric approach.
Cardiovascular outcomes, long-term safety, and weight regain after stopping treatment are unresolved. These questions need years of follow-up data. Published evidence covers only limited treatment durations.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.